Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Cancer

Last updated: October 7, 2021
Sponsor: Weprom
Overall Status: Active - Recruiting

Phase

N/A

Condition

Sarcopenia

Treatment

N/A

Clinical Study ID

NCT04804852
WP-2020-04
  • Ages > 18
  • All Genders

Study Summary

Sarcopenia is defined by the reduction in skeletal muscle mass and physical performance. It results in a decrease in muscle strength, overall physical activity, walking and the development of balance disorders and falls. It is one of the natural consequences of aging and contributes to frailty and the appearance of geriatric syndrome (s) (Chandapasirt et al, 2015; Cruz-Jentoft et al, 2010).

Its prevalence in patients with Head & Neck cancer is 39% (Hua et al, 2020) and is associated with an increase in postoperative complications (Achim et al, 2017; Bril et al, 2019), with greater toxicity of chemotherapy. (Wendrich et al, 2017) and reduced overall survival (Hua et al, 2020).

It is measured by CT scan (assessment of muscle volume with respect to L3 using IMAGE J software) (Teigen et al, 2018) and by clinical tests (performance tests) (Swartz et al, 2016, Cruz-Jentoft et al, 2010).

Several studies have shown a possible assessment of sarcopenia by measuring skeletal muscle mass with regard to C3 (Ufuk et al, 2019; Swartz et al, 2016).

This trial aims to evaluate the prevalence of sarcopenia in head and neck cancer evaluated by CT at C3.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • patient over 18 years old,
  • affiliated to the social security scheme,
  • suffering from locally advanced head & neck cancer (stages I to IVB) at diagnosis,
  • not operable,
  • justifying treatment by radiotherapy, whether or not associated with chemotherapy ortargeted therapy (eg: monoclonal antibodies, immunotherapy) whatever the proposedmodalities.

Exclusion

Exclusion Criteria:

  • patient treated by non-conservative surgery and cervical lymph node dissection makingit impossible to assess muscle mass with regard to C3,
  • metastatic disease,
  • minor patient,
  • adult patient under guardianship,
  • pregnancy or breastfeeding in progress.

Study Design

Total Participants: 50
Study Start date:
October 29, 2020
Estimated Completion Date:
May 30, 2022

Connect with a study center

  • Clinique Victor Hugo / Centre Jean Bernard

    Le Mans, 72000
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.